Cytokinetics' aficamten reduces heart muscle thickening in non-obstructive HCM trial
CYTK•Cytokinetics said ACACIA-HCM analyses found favorable cardiac remodeling and improved reported symptoms and quality of life with aficamten versus placebo in non-obstructive HCM. Benefits increased with longer treatment and faded after withdrawal.
1. Trial findings
Cytokinetics announced aficamten findings from analyses of the ACACIA-HCM trial in non-obstructive hypertrophic cardiomyopathy. The analyses showed favorable cardiac remodeling and improved patient-reported symptoms and quality of life versus placebo; reported benefits increased with longer treatment and faded after withdrawal.
2. Long-term safety findings
FOREST-HCM found transient, reversible heart-pumping dysfunction during long-term aficamten treatment for obstructive disease, with no associated heart failure hospitalizations or deaths. Aficamten, marketed as MYQORZO, is approved for symptomatic obstructive disease.
